Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 6:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 1,809 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Type 1 Diabetes Clear all
Recruiting Not applicable Interventional

Hybrid Closed Loop Effectiveness Trial in Adults With Type 1 Diabetes

NCT06236607
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Complications
Interventions
Device specific training, Study clinician/educator visit
Device · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 26, 2026, 6:53 PM EDT
Active, not recruiting Phase 1 Interventional

An Immunotherapy Vaccine (PIpepTolDC) for the Treatment of Patients With Type 1 Diabetes

NCT04590872
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Tolerogenic Dendritic Cell Vaccine
Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 45 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 26, 2026, 6:53 PM EDT
Completed Phase 2 Interventional

A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.

NCT00366379
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
GK Activator (2)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
10
States / cities
Chandler, Arizona • Oviedo, Florida • Nampa, Idaho + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 26, 2026, 6:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of PF-05175157 in Healthy Volunteers and Type 2 Diabetic Patients

NCT01396161
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PF-05175157 or Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
3
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Oct 26, 2026, 6:53 PM EDT
Completed No phase listed Observational

Desensitization for Highly Sensitized Recipients of Pancreas Transplantation

NCT00867386
View directory record Official record
Conditions
Type 1 Diabetes, Rejection of Pancreas Transplant, Desensitization
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 13, 2014 · Synced Oct 26, 2026, 6:53 PM EDT
Recruiting No phase listed Observational

The T1D Exchange Registry

NCT04629586
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes, Type 1 Diabetes, Diabetes Mellitus
Interventions
No intervention
Other
Lead sponsor
T1D Exchange, United States
Other
Eligibility
Not listed
Enrollment
50,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Oct 26, 2026, 6:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Insulin-Glucose-Glucagon Network: Defining a Type 1 Diabetes Progression Index

NCT02663661
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Metabolic Challenge Admission, CGM home test
Procedure · Other
Lead sponsor
University of Virginia
Other
Eligibility
12 Years to 45 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 26, 2026, 6:53 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes

NCT00308737
View directory record Official record
Conditions
Diabetes, Type 1, Diabetes, Type 2
Interventions
Technosphere® Insulin Inhalation Powder, Usual Care
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
2,053 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
82
States / cities
Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Oct 26, 2026, 6:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT)

NCT00915954
View directory record Official record
Conditions
Acromegaly, Type 2 Diabetes Mellitus
Interventions
Oral Glucose Tolerance Test, Subcutaneous administration of recombinant human IGF-1, Placebo
Diagnostic Test
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 26, 2026, 6:53 PM EDT
Completed Early Phase 1 Interventional

Early Markers of Disease and Response to Therapy

NCT04118153
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Abatacept
Drug
Lead sponsor
Sandra Lord, MD
Other
Eligibility
6 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Seattle, Washington • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 26, 2026, 6:53 PM EDT
Completed Not applicable Interventional

Diabetes Care Transformation: Diabetes Data Registry and Intensive Remote Monitoring

NCT02596204
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Weekly Review, FitBit
Other · Device
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
8 Years to 17 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 26, 2026, 6:53 PM EDT
Completed Not applicable Interventional

Safety of Low and Very Low Carbohydrate Diets in Young Children With Type 1 Diabetes

NCT03862521
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Diet Modification, Child, Only
Interventions
Low carbohydrate diet, Very low carbohydrate diet
Other
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
2 Years to 11 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Oct 26, 2026, 6:53 PM EDT
Completed Not applicable Interventional Results available

Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp®

NCT05224258
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
MiniMed 780G System
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
7 Years to 80 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
15
States / cities
Little Rock, Arkansas • Fresno, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 26, 2026, 6:53 PM EDT
Completed Phase 2 Interventional

Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes

NCT00064714
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
AC2993 (exenatide), daclizumab (immunosuppressive)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2015 · Synced Oct 26, 2026, 6:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Closed-loop Glucose Control for Automated Management of Type 1 Diabetes

NCT00811317
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Closed-loop
Device
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Oct 26, 2026, 6:53 PM EDT
Completed No phase listed Observational

The True Vie I3 Continuous Glucose Monitoring System in Pediatric Patients With Type 1 Diabetes Mellitus

NCT05908448
View directory record Official record
Conditions
T1DM - Type 1 Diabetes Mellitus
Interventions
13 CGM (continuous glucose monitor)
Device
Lead sponsor
Sinocare
Industry
Eligibility
2 Years to 17 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Oct 26, 2026, 6:53 PM EDT
Completed Phase 1 Interventional

Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg

NCT01546558
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Metformin, Ranolazine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
30 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 11, 2012 · Synced Oct 26, 2026, 6:53 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Role of Intestinal Inflammation in the Pathogenesis of Type 1 Diabetes

NCT01940835
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Upper endoscopy with small bowel biopsies and brushings., Blood draw, Stool sample
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 2, 2022 · Synced Oct 26, 2026, 6:53 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate Pneumococcal Polysaccharide Vaccine Effectiveness in Children With Type 1 Diabetes

NCT04481243
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Pneumovax 23- pneumococcal polysaccharide, Blood draw
Biological · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
3 Years to 18 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Oct 26, 2026, 6:53 PM EDT
Completed Not applicable Interventional Results available

Improving Diabetes in Emerging Adulthood

NCT04066959
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Motivational Enhancement System (MES), Question Prompt List (QPL), Text Message Reminders (TXT)
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
16 Years to 25 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 26, 2026, 6:53 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

GPR119 Agonist for Hypoglycemia in Type 1 Diabetes

NCT04432090
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Placebo, Study Medication (MBX-2982), No medication for this group
Drug · Other
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
20 Years to 60 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 26, 2026, 6:53 PM EDT
Active, not recruiting Phase 1 Interventional

Islet Transplantation Alone (ITA) in Patients With Difficult to Control Type I Diabetes Mellitus Using a Glucocorticoid-free Immunosuppressive Regimen

NCT00706420
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Islet Transplantation + Immunosuppression, Islet cell transplantation
Procedure · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 26, 2026, 6:53 PM EDT
Completed No phase listed Observational

AbATE Follow-Up Study

NCT02067923
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
10 Years to 37 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 26, 2026, 6:53 PM EDT
Terminated Phase 1 Interventional Results available

A Research Trial of Aralast in New Onset Diabetes (RETAIN)

NCT01183468
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Aralast NP 45 mg dose, Aralast NP 90 mg dose, Aralast NP 180 mg dose
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 35 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
15
States / cities
San Diego, California • Aurora, Colorado • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Oct 26, 2026, 6:53 PM EDT